What is AmyTrap
AmyTrap is a patented molecule composed of polymer-bound short peptides with the capacity to capture beta-amyloid (Aβ) peptide. The polymer moiety is conjugated to albumin. Amytrap binds and sequesters Aβ from the circulation, leading to the depletion of amyloid plaques from the brain in model mice. Recombinant Technologies has developed and tested three versions of the compound (AmyTrap 2, AmyTrap 3 and AmyTrap 4) containing distinct small molecule peptides. We have shown in the Alzheimer's diseases mouse models that subcutaneously injected AmyTrap significantly reduced the Aβ plaque burden in the brain and improved the cognitive parameters of these mice. Our preliminary studies suggest that AmyTrap does not enter the brain. Undetectable levels of AmyTrap and reduction of the Aβ burden in the brain suggest that the AmyTrap possibly exerts its therapeutic activity by acting as peripheral sink for circulatory Aβ. Based on these observations it has been hypothesized that Aβ exists in equilibrium between the brain and in circulation. Sequestration of the circulatory Aβ in the periphery creates an imbalance in this equilibrium driving efflux of Aβ from the brain into the circulation.
We are excited about the promising results AmyTrapper has shown up to this point. We are looking for people and organizations that can help us bring this technology to the next level through further research and the initiation of human trials.
If you would like to learn more about the technology or meet our team of innovators, please fill out the form below.